Evaluating the Real-World Effectiveness of Systemic Treatments in Atopic Dermatitis Using the Atopic Dermatitis Control Tool (ADCT): A Multi-Centre, Prospective Study
DOI:
https://doi.org/10.2340/actadv.v105.40704Keywords:
atopic dermatitis, Atopic Dermatitis Control Tool, dupilumab, cyclosporineAbstract
Atopic dermatitis is a chronic skin disease affecting quality of life, sleep, and mental health. Traditional evaluation methods focus on clinical assessments, but there is a growing need for tools that incorporate patient-reported outcomes (PROs). To evaluate the effectiveness of the Atopic Dermatitis Control Tool (ADCT) in assessing disease severity in patients with moderate to severe atopic dermatitis and to compare the efficacy of systemic immunosuppressants and dupilumab in patients with moderate to severe atopic dermatitis. A prospective, observational study was conducted across seven centres in Korea, involving 112 patients with moderate to severe atopic dermatitis. The ADCT, Eczema Area and Severity Index (EASI), and Dermatology Life Quality Index (DLQI) were used for assessing atopic dermatitis severity. In addition, the study assessed the effectiveness of immunosuppressants and dupilumab over the course of one year. The study found significant correlations between ADCT scores and other severity measures (EASI, DLQI). The correlation coefficients were 0.54 (p < 0.0001) for ADCT vs EASI and 0.83 (p < 0.0001) for ADCT vs DLQI. Furthermore, patients treated with dupilumab exhibited greater improvement compared with those on cyclosporine, as measured by the ADCT (adjusted OR [95% CI]); 6.98 [2.49, 19.58]). The ADCT effectively captures subjective aspects compared with the EASI and can be used practically and effectively in clinical settings of atopic dermatitis.
Downloads
References
Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection. J Allergy Clin Immunol Pract 2020; 8: 91-101.
https://doi.org/10.1016/j.jaip.2019.06.044 DOI: https://doi.org/10.1016/j.jaip.2019.06.044
Wei W, Anderson P, Gadkari A, Blackburn S, Moon R, Piercy J, et al. Discordance Between Physician- and Patient-Reported Disease Severity in Adults with Atopic Dermatitis: A US Cross-Sectional Survey. Am J Clin Dermatol 2017; 18: 825-835.
https://doi.org/10.1007/s40257-017-0284-y DOI: https://doi.org/10.1007/s40257-017-0284-y
Schmitt J, Spuls PI, Thomas KS, Simpson E, Furue M, Deckert S, et al. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol 2014; 134: 800-807.
https://doi.org/10.1016/j.jaci.2014.07.043 DOI: https://doi.org/10.1016/j.jaci.2014.07.043
Pariser DM, Simpson EL, Gadkari A, Bieber T, Margolis DJ, Brown M, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin 2020; 36: 367-376.
https://doi.org/10.1080/03007995.2019.1699516 DOI: https://doi.org/10.1080/03007995.2019.1699516
Simpson E, Eckert L, Gadkari A, Mallya UG, Yang M, Nelson L, et al. Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol 2019; 19: 15.
https://doi.org/10.1186/s12895-019-0095-3 DOI: https://doi.org/10.1186/s12895-019-0095-3
Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 2014; 71: 116-132.
https://doi.org/10.1016/j.jaad.2014.03.023 DOI: https://doi.org/10.1016/j.jaad.2014.03.023
Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol 2018; 32: 657-682.
https://doi.org/10.1111/jdv.14891 DOI: https://doi.org/10.1111/jdv.14891
Kim JE, Shin MK, Park GH, Lee UH, Lee JH, Han TY, et al. 2019 Consensus Korean Diagnostic Guidelines to Define Severity Classification and Treatment Refractoriness for Atopic Dermatitis: Objective and Subjective Assessment of Severity. Ann Dermatol 2019; 31: 654-661.
https://doi.org/10.5021/ad.2019.31.6.654 DOI: https://doi.org/10.5021/ad.2019.31.6.654
Lee JH, Kim JE, Park GH, Bae JM, Byun JY, Shin MK, et al. Consensus Update for Systemic Treatment of Atopic Dermatitis. Ann Dermatol 2021; 33: 497-514.
https://doi.org/10.5021/ad.2021.33.6.497 DOI: https://doi.org/10.5021/ad.2021.33.6.497
Saeki H, Ohya Y, Furuta J, Arakawa H, Ichiyama S, Katsunuma T, et al. English Version of Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021. J Dermatol 2022; 49: e315-e375.
https://doi.org/10.1111/1346-8138.16527 DOI: https://doi.org/10.1111/1346-8138.16527
Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, et al. Executive summary: Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol 2024; 90: 342-345.
https://doi.org/10.1016/j.jaad.2023.08.103 DOI: https://doi.org/10.1016/j.jaad.2023.08.103
Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol 2014; 133: 429-438.
https://doi.org/10.1016/j.jaci.2013.07.049 DOI: https://doi.org/10.1016/j.jaci.2013.07.049
Staumont-Sallé D, Taieb C, Merhand S, Shourick J. The Atopic Dermatitis Control Tool: A High-Performance Tool for Optimal Support. Acta Derm Venereol 2021; 101: adv00618.
https://doi.org/10.2340/actadv.v101.750 DOI: https://doi.org/10.2340/actadv.v101.750
Kido-Nakahara M, Yokote G, Yoshida M, Furue M, Nakahara T. Atopic Dermatitis Control Tool (ADCT): A useful tool for self-evaluation in patients with atopic dermatitis. J Dermatol 2021; 48: 1951-1952.
https://doi.org/10.1111/1346-8138.16176 DOI: https://doi.org/10.1111/1346-8138.16176
Nakahara T, Fujita H, Tajima Y, Arima K. Evaluating the usefulness of the Atopic Dermatitis Control Tool for assessing disease control in individuals with atopic dermatitis in Japan. Br J Dermatol 2023; 190: 123-125.
https://doi.org/10.1093/bjd/ljad344 DOI: https://doi.org/10.1093/bjd/ljad344
Luan TT, Peng CY, Song XT, Liao SL, Zhao ZT. [Validation study of the Chinese version of atopic dermatitis control tool]. Zhonghua Yu Fang Yi Xue Za Zhi 2023; 57: 422-426.
Wallace DV. Treatment options for moderate to severe atopic dermatitis. Allergy Asthma Proc 2022; 43: 474-493.
https://doi.org/10.2500/aap.2022.43.220076 DOI: https://doi.org/10.2500/aap.2022.43.220076
Hartmann J, Moitinho-Silva L, Sander N, Harder I, Häsler R, Rodriguez E, et al. Dupilumab but not cyclosporine treatment shifts the microbiome toward a healthy skin flora in patients with moderate-to-severe atopic dermatitis. Allergy 2023; 78: 2290-2300.
https://doi.org/10.1111/all.15742 DOI: https://doi.org/10.1111/all.15742
Merola JF, Chiou AS, During E, Costanzo A, Foley P, Alfalasi A, et al. Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study. Br J Dermatol 2023; 189: 685-694.
https://doi.org/10.1093/bjd/ljad284 DOI: https://doi.org/10.1093/bjd/ljad284
Milanesi N, Gola M, Cartocci A, Tronconi G, Bruzziches F, Flori ML, et al. Effect of dupilumab on sleep disturbances in adult patients with severe atopic dermatitis. Ital J Dermatol Venerol 2022; 157: 142-145.
https://doi.org/10.23736/S2784-8671.21.07072-9 DOI: https://doi.org/10.23736/S2784-8671.21.07072-9
Simpson EL. Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials. Dermatol Ther (Heidelb) 2017; 7: 243-248.
https://doi.org/10.1007/s13555-017-0181-6 DOI: https://doi.org/10.1007/s13555-017-0181-6
Lee SE, Hopkins C, Mullol J, Msihid J, Guillemin I, Amin N, et al. Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies. Allergy 2022; 77: 2211-2221.
https://doi.org/10.1111/all.15222 DOI: https://doi.org/10.1111/all.15222
Miniotti M, Lazzarin G, Ortoncelli M, Mastorino L, Ribero S, Leombruni P. Impact on health-related quality of life and symptoms of anxiety and depression after 32 weeks of Dupilumab treatment for moderate-to-severe atopic dermatitis. Dermatol Ther 2022; 35: e15407.
https://doi.org/10.1111/dth.15407 DOI: https://doi.org/10.1111/dth.15407
Downloads
Additional Files
Published
How to Cite
License
Copyright (c) 2025 Hyun Ji Lee, Yuri Woo, Young Bok Lee, Ji Hye Lee, Jung Eun Kim, Ji Hyun Lee, Sang Hyun Cho
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
